Akari Therapeutics PlcAKTXCash flow

Market cap
$16.5B
P/E ratio
2013/122014/122015/122016/122017/122018/122019/122020/122021/122022/122023/122024/12
Depreciation & amortization---39,94442,40035,84819,2058,9074,1263,70800
Stock-based compensation2014321325,523314,650735,10712
Cash from operations -5-9-4,965,583-24,624,535-31,598,709-22,580,240-12,918,313-16,950,408-18,846,528-21,504,522-16-13
Capital expenditures-0-0-10,560-54,750-36,885-------
Cash from investing --01-10,066,63210------0
Cash from financing 24869-16306,23213251425711
Free cash flow-----